May 8, 2019 10:33 AM EDT

BioNTech nabs PhI antibody and a new US base out of bankruptcy; Pfizer wins conditional drug OK

ENDPOINTS

→ BioNTech is buying MabVax’s labs $MBVX and a clinical asset out of bankruptcy as the German mRNA company establishes a satellite operation in San …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BioNTech nabs PhI antibody and a new US base out of bankruptcy; Pfizer wins conditional drug OK

ENDPOINTS

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

Teva launches Stelara biosimilar at 85% discount as wider field emerges

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

BioN­Tech nabs PhI an­ti­body and a new US base out of bank­rupt­cy; Pfiz­er wins con­di­tion­al drug OK

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

BioNTech nabs PhI antibody and a new US base out of bankruptcy; Pfizer wins conditional drug OK